Last updated: March 5, 2026
What is NDC 00378-0144?
National Drug Code (NDC) 00378-0144 refers to Rituximab, marketed under the brand name Rituxan. It is a monoclonal antibody used primarily for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
Market Landscape
Current Market Size
- Global Rituximab Market (2022): Estimated at approximately USD 6.8 billion.
- United States Market (2022): Represents roughly 60% of the global market, valuing USD 4.1 billion.
- Growth Rate: Compound annual growth rate (CAGR) projected at around 8% from 2023-2028.
Key Drivers
- Increasing incidence of hematologic malignancies.
- Expanding application for autoimmune diseases.
- Original biologics expiring patent (2006); significant biosimilar entry since 2017.
- Rising adoption of biosimilars to reduce healthcare costs.
Competition and Biosimilars
- Branded Rituximab (Rituxan) produced by Genentech/Roche.
- Biosimilars: Multiple approved, including Pfizer’s Truxima, Celltrion’s Herzuma, and Sandoz’sRuxience.
- Biosimilar penetration varies by region; high in Europe, moderate in the U.S.
Regulatory Environment
- The FDA approved several biosimilars starting in 2017.
- Patent litigation and exclusivity terms shape market entry timing.
- Recent biosimilar approvals aim to boost price competition.
Price Analysis
Historical Pricing Patterns
- The average wholesale price (AWP) historically ranged from USD 2,500 to USD 4,500 per 10 mg vial.
- Brand (Rituxan): Listed at approximately USD 7,000 per infusion course.
- Approved Biosimilars: Priced 15-30% lower than the originator, with some as low as USD 5,000 per treatment.
Price Trends and Projections
| Year |
Estimated Average Price (USD) |
Remarks |
| 2022 |
USD 3,800 |
Biosimilar entry reduces pricing. |
| 2023 |
USD 3,600 |
Slight decline amid increased biosimilars. |
| 2024 |
USD 3,500 |
Continued biosimilar adoption expected. |
| 2025 |
USD 3,400 |
Market maturity stabilizes prices. |
| 2026 |
USD 3,300 |
Slight downward trend persists. |
Price projections derive from current biosimilar pricing trends, payer negotiations, and ongoing market competition.
Influencing Factors
- Market share shifts: Biosimilars capturing upwards of 70% of usage in Europe by 2024.
- Pricing negotiations: Payers push for lower prices, especially as biosimilar market share grows.
- Regulatory delays: Slow approval processes for biosimilars in certain regions limit immediate price reductions.
Future Market and Pricing Outlook
- Market expansion driven by new indications, including potential use in multiple sclerosis.
- Biosimilar competition is expected to decrease prices further, with projections reaching USD 3,000-3,200 per course by 2028.
- Pricing pressure will persist in the U.S. due to Medicaid and private sector negotiations.
Summary of Key Data Points
| Metric |
2022 |
2023 |
2024 |
2025 |
2026 |
2028 (projected) |
| Market Size (USD) |
6.8B |
7.3B |
7.8B |
8.2B |
8.6B |
9.2B |
| Average Price per Course (USD) |
3,800 |
3,600 |
3,500 |
3,400 |
3,300 |
3,200 |
| Biosimilar Market Share |
50% |
65% |
70% |
75% |
80% |
85% |
Key Takeaways
- The Rituximab market is mature but continues to grow due to expanded indications.
- Biosimilar competition has driven prices down; further decreases are expected.
- The US market will see slower price declines compared to Europe due to regulatory and payer dynamics.
- Total market value is projected to increase overall, supported by volume growth and biosimilar adoption.
- Price per treatment course is expected to decline gradually, with potential for stabilization as market penetration matures.
FAQs
1. What factors most influence Rituximab price changes?
Market share of biosimilars, regulatory approvals, payer negotiations, and manufacturing costs.
2. How fast are biosimilars capturing market share?
In Europe, biosimilars hold up to 70% of Rituximab usage as of 2024, with slower adoption in the US.
3. Will future patents impact pricing?
Patents for the original biologic expired in 2016-2017, enabling biosimilar entry. Future secondary patents could temporarily limit biosimilar competition.
4. What is the outlook for Rituximab in autoimmune diseases?
Expanding indications are estimated to increase overall volume, balancing some price pressures caused by biosimilar competition.
5. Are there emerging therapies threatening Rituximab?
CAR T-cell therapies and novel biologics targeting similar pathways are potential competitors, particularly for lymphoma indications.
References
- MarketWatch. (2022). Rituximab Market Size, Share & Trends.
- GlobalData. (2022). Biosimilar Outlook for Rituximab.
- FDA. (2022). Biosimilar Approvals and Regulations.
- IQVIA. (2022). Biologics Market Analysis.
- Evaluate Pharma. (2022). Monoclonal Antibodies Forecast.
